6/8/2023 | BKHYIG | Moody's assigns Ba3 to Fortrea notes
|
6/8/2023 | BKHYIG | Fitch rates Fortrea notes BB+
|
6/1/2023 | BKHYIG | Fitch assigns BB+ to Fortrea, facility
|
10/1/2018 | CV | LabCorp says 0% notes due 2021 remain convertible through December
|
10/12/2016 | CVIG | Moody’s ups LabCorp view to stable
|
7/23/2015 | HY | Labco/Synlab sets pricing on upsized €1.06 billion three-part notes ahead of final terms Thursday
|
11/3/2014 | PP | Market Commentary: American Realty bonds take another leg lower; Omnicare higher; Owens-Illinois sets tender
|
11/3/2014 | CV | Market Commentary: American Realty bonds take another leg lower; Omnicare higher; Owens-Illinois sets tender
|
11/3/2014 | BK | LabCorp eyes $1 billion term loan, $2.9 billion of bond funding for $6 billion Covance acquisition
|
11/3/2014 | CVIG | S&P puts LabCorp on watch
|
11/3/2014 | CV | Market Commentary: Morning Commentary: American Realty moves lower; LabCorp shares down on acquisition news
|
10/1/2014 | CV | LabCorp says zero-coupon notes now convertible through December
|
9/12/2014 | CV | LabCorp: 0% convertibles accrue contingent cash interest to March 11
|
7/1/2014 | CV | LabCorp says zero-coupon notes now convertible through September
|
4/1/2014 | CV | LabCorp's zero-coupon notes now convertible through June 30
|
3/11/2014 | CV | LabCorp says zero-coupon convertibles to accrue interest to Sept. 11
|
12/13/2013 | CVIG | S&P upgrades LabCorp to BBB+
|
10/30/2013 | IG | Market Commentary: Proctor & Gamble, Colgate price as primary pauses; Coca-Cola, LabCorp 10-year notes tighten
|
10/29/2013 | IG | Market Commentary: Coca-Cola, Altera, LabCorp continue primary frenzy; Coca-Cola, LabCorp trade flat to better
|
10/29/2013 | BK | LabCorp to pay down credit facility debt with senior note proceeds
|
10/29/2013 | CVIG | Moody's rates LabCorp notes Baa2
|
10/29/2013 | CVIG | S&P assigns LabCorp notes BBB
|
10/29/2013 | IG | LabCorp to price senior notes due 2018 and 2023 in two tranches
|
10/29/2013 | IG | New Issue: LabCorp sells $700 million of five-, 10-year senior notes in two parts
|
10/1/2013 | CV | LabCorp holders may now convert zero-coupon notes through year-end
|
9/12/2013 | CV | LabCorp says zero-coupon convertibles to accrue interest to mid-March
|
7/1/2013 | CV | LabCorp holders may convert zero-coupon notes through Sept. 30
|
4/8/2013 | CV | LabCorp holders may convert zero-coupon notes through June 28
|
3/25/2013 | CVIG | Moody's: LabCorp view stable
|
3/11/2013 | CV | LabCorp 0% convertibles accrue contingent cash interest to Sept. 11
|
1/9/2013 | CVIG | S&P lowers LabCorp
|
1/2/2013 | CV | LabCorp holders may convert zero-coupon notes through March 29
|
10/1/2012 | CV | LabCorp holders may convert zero-coupon notes due 2021 through Dec. 31
|
9/12/2012 | CVLM | LabCorp to pay $1.48 contingent cash interest on convertibles due 2021
|
8/20/2012 | IG | Market Commentary: LabCorp, AIG, Domtar, Unum price as deal pace slows; new issues mixed in secondary market
|
8/20/2012 | BK | LabCorp plans to repay revolver borrowings using notes offer proceeds
|
8/20/2012 | CVIG | Moody's rates LabCorp notes Baa2
|
8/20/2012 | CVIG | S&P rates LabCorp notes BBB+
|
8/20/2012 | IG | New Issue: LabCorp sells $1 billion of senior notes in five-, 10-year tranches
|
8/17/2012 | BKCVIG | Moody's LabCorp view positive
|
7/2/2012 | CV | LabCorp announces conversion right for 0% notes through Sept. 18
|
4/2/2012 | CVLM | LabCorp's zero-coupon notes now convertible through June 29
|
3/13/2012 | CV | Laboratory Corp. of America's convertibles to accrue cash interest
|
1/3/2012 | CVLM | LabCorp says 0% notes convertible for another quarter through March
|
12/21/2011 | BK | LabCorp gets $1 billion five-year revolving senior credit facility
|
12/9/2011 | CVIGPF | Laboratory Corp. files automatic shelf for debt, preferreds and stock
|
10/6/2011 | CV | LabCorp says zero-coupon notes remain convertible for another quarter
|
9/13/2011 | CV | LabCorp 0% convertibles accrue contingent cash interest to March 11
|
9/12/2011 | CVLM | LabCorp holders put back no 0% convertible subordinated notes due 2021
|
7/1/2011 | CV | LabCorp holders may continue to convert 0% notes for three more months
|
4/4/2011 | CV | LabCorp's 0% convertible notes due 2021 are convertible to June 30
|
3/14/2011 | CVLM | LabCorp to pay contingent cash interest on 0% convertibles due 2021
|
1/3/2011 | CV | LabCorp's 0% convertible subordinated notes due 2021 are convertible
|
11/16/2010 | CVIG | S&P rates LabCorp notes BBB+
|
11/16/2010 | CVIG | Moody's rates LabCorp notes Baa2
|
11/16/2010 | IG | New Issue: Lab Corp. of America sells $925 million of notes due 2016, 2020
|
11/16/2010 | IG | Market Commentary: LabCorp, GATX, Telephone & Data price deals on stronger tone; bank, financial paper weaker
|
10/4/2010 | CV | LabCorp's 0% convertible subordinated notes due 2021 are convertible
|
9/14/2010 | CVIG | Moody's drops LabCorp outlook to stable
|
9/13/2010 | CV | LabCorp's 0% convertible notes due 2021 to accrue contingent interest
|
9/13/2010 | BWCVIG | LabCorp to use revolver, bonds for $925 million acquisition of Genzyme
|
7/1/2010 | CV | LabCorp's 0% convertible subordinated notes due 2021 are convertible
|
6/4/2010 | CVIG | Moody's upgrades LabCorp
|
4/6/2010 | CV | LabCorp 0% subordinated notes due 2021 convertible into cash, stock
|
3/26/2010 | CV | LabCorp convertibles to accrue contingent cash interest to Sept. 11
|
1/5/2010 | CV | LabCorp 0% convertible subordinated notes conversion rights triggered
|
9/21/2009 | CVIG | Moody's ups LabCorp outlook to positive
|
8/20/2009 | CVIG | S&P boosts LabCorp
|
8/4/2009 | SS | LabCorp completes tender offer, acquisition of Monogram Biosciences
|
7/28/2009 | SS | LabCorp extends $4.55-per-share tender offer for Monogram Biosciences
|
7/17/2009 | SS | LabCorp clears antitrust wait period to acquire Monogram Biosciences
|
7/1/2009 | CV | LabCorp redeems all remaining LYONs, half of zero-coupon convertibles
|
7/1/2009 | SS | LabCorp starts tender offer for Monogram Biosciences shares
|
6/30/2009 | CVIG | S&P: LabCorp on positive watch
|
6/23/2009 | SS | LabCorp to buy Monogram Biosciences in deal valued at $106.7 million
|
6/23/2009 | SS | Market Commentary: Analyst says Huntsman settled too low; Tower revs up deal plans; Monogram stock soars on bid
|
5/12/2009 | CVIG | Moody's: LabCorp unchanged
|
5/11/2009 | CV | LabCorp calls all remaining LYONs, half of remaining 0% convertibles for redemption
|
3/6/2009 | CV | Market Commentary: Financials, Wells Fargo weak, but in line with stock; Qwest adds 0.25 point; LabCorp finds buyers
|
1/23/2009 | SS | Longview Asset Management cuts stake in LabCorp to 4.96%
|
12/5/2008 | CVIG | Laboratory Corp. of America files automatic shelf
|
10/14/2008 | SS | Longview Asset Management sells 704,592 shares of LabCorp
|
10/1/2008 | CV | LabCorp's LYONs, 0% convertibles remain convertible in fourth quarter
|
9/12/2008 | CV | LabCorp to pay contingent interest on LYONs, 0% convertibles
|
7/1/2008 | CV | LabCorp's notes due 2021 remain convertible
|
4/1/2008 | CV | LabCorp announces LYONs, 0% convertibles remain convertible through second quarter
|
3/12/2008 | CV | LabCorp holders to receive contingent interest on LYONs, 0% convertibles
|
1/4/2008 | CV | LabCorp says holders may convert LYONs, 0% convertibles in fourth quarter
|
10/26/2007 | CVIG | S&P affirms LabCorp
|
10/26/2007 | CVIG | Moody's affirms LabCorp
|
10/3/2007 | CV | Holders may convert LabCorp. LYONs, 0% convertibles for fourth quarter
|
9/12/2007 | CV | LabCorp LYONs, zero-coupon convertibles to pay contingent interest
|
7/24/2007 | CV | LabCorp says holders may convert LYONs, 0% convertibles for third quarter
|
4/16/2007 | CV | LabCorp says holders may convert LYONs, 0% convertibles in second quarter
|
3/19/2007 | CV | LabCorp LYONs, zero-coupon convertibles to pay contingent interest
|
3/2/2007 | SS | Laboratory Corp. investors, led by Longview, increase stake in company to 6.2%
|
1/9/2007 | CV | LabCorp says holders may convert LYONs, 0% convertibles in first quarter
|
10/24/2006 | BT | LabCorp third-quarter cash flow $155 million, announces stock repurchase plan
|
10/23/2006 | BTCV | LabCorp exchanges 99% of LYONs due 2021
|
10/2/2006 | BTCV | LabCorp says LYONs due 2021 will be convertible for fourth quarter
|
9/22/2006 | BTCV | LabCorp noteholders put $34,000 LYONs
|
9/22/2006 | BTCV | LabCorp starts net share settlement exchange offer for LYONs due 2021
|
9/19/2006 | BT | LabCorp plans to grow profits by increasing esoteric business
|
9/19/2006 | BTCV | LabCorp LYONs to pay contingent interest
|
6/13/2006 | BT | LabCorp, Duke to offer new genomic tests
|
2/23/2006 | BT | LabCorp to commercialize Yale's blood testing technology for ovarian cancer
|
2/13/2006 | BT | LabCorp offers UGT1A1 pharmacogenetic test for dosing colorectal cancer therapy
|
1/18/2006 | CV | Market Commentary: Techs dominate convertibles market; Intel drops outright but expands on a hedged basis, AMD adds
|
1/18/2006 | BT | Market Commentary: KV Pharmaceutical stock up on patent ruling; biotech offerings take a back seat to tech market
|
1/5/2006 | CV | Market Commentary: Convertible market extends broad-based gains; autos, biotechs lift; Fannie Mae adds
|
12/9/2005 | BT | New Issue: LabCorp sells $250 million 10-year notes to yield 5.663%
|
12/8/2005 | BKBTCV | Moody's rates LabCorp notes Baa3
|
12/8/2005 | BKBTCV | S&P rates LabCorp notes BBB
|
12/8/2005 | BT | LabCorp to sell $250 million 10-year senior notes to partly fund $500 million stock buybacks
|
12/8/2005 | BT | Market Commentary: Voyager rejigs IPO talk, cuts size; QLT plunges on severe cutbacks; LabCorp up sharply on buyback
|
12/8/2005 | CV | Market Commentary: New SafeNet convertibles gain with shares; technology and biotech firmer; LabCorp gains
|
12/7/2005 | BT | LabCorp board approves $500 million stock repurchase program, to buy $250 million immediately
|
12/1/2005 | BT | Market Commentary: Rigel Pharma tromped; Oxigene, Biopure launch follow-on deals; Lexicon, LabCorp, Quigley higher
|
11/3/2005 | BT | Bionomics licenses epilepsy tests to LabCorp
|
11/1/2005 | BT | LabCorp licenses Arcturus Bioscience's technology for cancer of unknown primary origin
|
3/31/2005 | CV | S&P: Lab Corp. unaffected
|
1/12/2005 | CV | Lehman adds LabCorp convert to recommended portfolio on robust stock outlook
|
12/16/2004 | CV | S&P: Lab Corp. unaffected
|
9/13/2004 | CV | Laboratory Corp. of America put not exercised on zero-coupon notes
|
12/18/2003 | CV | S&P: LabCorp unaffected by stock purchase
|
3/11/2003 | CV | New Issue: Salomon sells $10.35 million 0.5% notes exchangeable for LabCorp
|
2/27/2003 | CV | New Issue: Goldman sells $5 million 0.5% notes exchangeable for LabCorp
|
1/28/2003 | CV | Moody's rates new LabCorp Baa3
|
1/15/2003 | CV | Fitch rates State Street convertible AA-
|
11/11/2002 | CV | S&P notes AES tender extension
|
10/4/2002 | CV | Market Commentary: LabCorp, TXU slammed hard on huge sell-off after latest warnings
|
5/14/2002 | HY | Moody's cuts Solectron
|
5/9/2002 | CV | Moody's lowers WorldCom to junk
|